Novo Nordisk Seeks FDA, EMA Approval For Sickle Cell Disease Treatment – Here Are The Key Takeaways
Novo Nordisk said etavopivat could offer a new disease-modifying treatment option for people living with sickle cell disease if approved.
Novo Nordisk said etavopivat could offer a new disease-modifying treatment option for people living with sickle cell disease if approved.